Engineered immune cells take aim at Hard-to-Treat leukemia

NCT ID NCT06071624

First seen Nov 04, 2025 · Last updated May 04, 2026 · Updated 32 times

Summary

This early-stage trial tests a new treatment for chronic myelomonocytic leukemia (CMML) that has returned or not responded to standard therapy. The treatment uses a patient's own immune cells, modified to target and attack cancer cells. The main goals are to find a safe dose and see if the therapy can reduce cancer cells in the bone marrow.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC MYELOMONOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Albert Einstein Health Network

    NOT_YET_RECRUITING

    The Bronx, New York, 10467, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center

    RECRUITING

    Indianapolis, Indiana, 46202, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The University of Texas MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida 33136

    RECRUITING

    Miami, Florida, 33136, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.